Home » Imatinib » A malaria treatment is shown to be 100% effective in just 3 days in a Phase 2 trial
Progress

A malaria treatment is shown to be 100% effective in just 3 days in a Phase 2 trial

A repurposed cancer drug has been shown to be 100% effective in treating malaria in a Phase 2 clinical trial. Purdue University professor Philip Low led the international team that made the discovery. (Purdue University photo/John Underwood)

A repurposed cancer drug has been shown to be 100% effective in treating malaria in a Phase 2 clinical trial. Purdue University professor Philip Low led the international team that made the discovery.

(Purdue University photo/John Underwood)

A cancer drug repurposed to treat malaria has been shown to be nearly 100% effective in helping defeat the disease in just three days, according to the results of a Phase 2 clinical trial.

The results of the trial were published Thursday (Aug. 26) in the Journal of Experimental Medicine.

The trial shows that the addition of the drug Imatinib to the customary malaria therapy enables clearance of all malaria parasites from 90% of patients within 48 hours and from 100% of patients within three days, says Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, who co-directed the international research team. The patients receiving Imatinib also were relieved of their fevers in less than half of the time experienced by similar patients treated with the standard therapy.

“In our trial, 33% of the patients treated with the standard therapy (but without the Imatinib supplement) still suffered from significant parasitemia after three days,” said Low (rhymes with “now”). “Delayed clearance rates are a precursor to and an indicator of potential drug resistance, which has been a problem with malaria for decades. So, this could be significant.”

Imatinib was originally produced by Novartis for the treatment of chronic myelogenous leukemia and other cancers. It works by blocking specific enzymes involved in the growth of cancers.

“When we discovered the ability of Imatinib to block parasite propagation in human blood cultures in petri dishes, we initiated a human clinical trial where we combined Imatinib with the standard treatment (piperaquine plus dihydroartemisinin) used to treat malaria in much of the world,” Low said. “The Phase 2 clinical trial that is described in the paper in Journal of Experimental Medicine compares the standard treatment with Imatinib plus the standard treatment. We did not test Imatinib alone, because it would have been unethical to treat patients suffering from a potentially lethal disease with an untested therapy.”

Malaria infects human red blood cells, where it reproduces and eventually activates a red blood cell enzyme that, in turn, triggers rupture of the cell and release of a form of the parasite called a merozoite into the bloodstream. Low and his colleagues theorized that by blocking the critical red blood cell enzyme, they could stop the infection. The data from the drug trial confirms that.

Low said for the past 50 years, malaria treatments have used drugs that target the parasite itself, but the microorganism eventually developed resistance to the drugs.

“Because we’re targeting an enzyme that belongs to the red blood cell, the parasite can’t mutate to develop resistance — it simply can’t mutate proteins in our blood cells,” Low said. “This is a novel approach that will hopefully become a therapy that can’t be evaded by the parasite in the future. This would constitute an important contribution to human health.”

Malaria is caused by a single-cell parasite, Plasmodium, which is carried by mosquitoes. The World Health Organization estimates that the disease caused 409,000 deaths in 2019 (the most recent year for which data is available). The WHO also notes that 67% of those deaths were in children under 5 years old.

The deadliest form of the parasite is P. falciparum, and although most malaria deaths occur in sub-Saharan Africa, a variant of P. falciparum that is developing drug resistance has become established in a corner of Southeast Asia, particularly in Cambodia, Myanmar, Thailand, Laos and Vietnam. In some regions of the area, up to 80% of malaria parasites are at least partially drug resistant.

In 2019, professor Olivo Miotto from the Wellcome Sanger Institute of the University of Oxford, told the BBC the rise of the drug-resistant variant in Southeast Asia raises the “terrifying prospect” of the drug-resistant variety traveling to Africa. A similar event occurred in the 1980s with malaria resistant to the then-standard treatment of chloroquine, which resulted in millions of deaths.

Low and his colleagues tested Imatinib in a hot zone of drug-resistant malaria on the border of Vietnam and Laos, in the Quang Tri Province of Vietnam.

“It’s such a remote region of the country that most of the clinics are one- or two-room cinder block buildings with just six or seven cots where people can come in and get treated,” Low said. “Not only was the drug 100% effective after three days, but the patients saw their fever disappear on the first day, and they felt much better sooner.”

Although malaria is not a significant disease in North America, Low is planning to apply for approval by the U.S. Food and Drug Administration.

“The FDA is so widely respected around the world that if they approve it, almost all other nations, especially developing countries that suffer from malaria, will rapidly adopt it,” he said. “The FDA requirements for Phase 3 approval are very rigorous. You have to demonstrate the drug combination’s efficacy and safety in a large patient population and then show that you can manufacture and store it safely and reproducibly. You also have to start from scratch and end up with a product that is more than 99% pure.”

An international priority patent application has been filed in Vietnam by Purdue Research FoundationVinUniversity in VietnamUniversity of Sassari in Italy and Italian company NUREX SRL.

Low said he has been in discussions with drug manufacturers in India and Vietnam to produce the drug and estimates that can be done for roughly $1 per pill.

“We’ll turn over the technology to any company committed to distributing it to developing malaria-infested areas,” he said. “I’m not interested in making a penny off of this. I just think it’s important for humanity to have it.”

 

Original Article: Malaria treatment shown to be 100% effective in Phase 2 trial

More from: Purdue University 

 

The Latest on: Imatinib and malaria

  • Timothy R. Hughes
    on July 28, 2022 at 5:00 pm

    Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant ... Injury in an Experimental Malaria Model Fiona E.

  • Tyrosine News and Research
    on July 27, 2022 at 5:00 pm

    A new method to combat malaria which sees the disease turn against ... Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research ...

  • Chemotherapy drugs from 'rogue' online pharmacies could endanger leukemia patients
    on July 27, 2022 at 5:00 pm

    A survey of online pharmacies claiming to sell the oral chemotherapy drug imatinib found that only three of the 44 identified English-language sites that shipped within the United States were ...

  • How T cells safeguard the frontline from viral infections and certain cancers
    on July 27, 2022 at 5:09 am

    Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have identified how to increase the ability of tissue-resident memory T (TRM) cells to help fight viral ...

  • Abortion bans may limit treatment options for cancer patients
    on July 12, 2022 at 8:08 am

    like methotrexate or imatinib (Gleevec), Coussens and Gralow said. Pharmacy chains like Walgreens, CVS and Walmart have all started to limit access to methotrexate in states where that drug's ...

  • Illness after International Travel
    on February 26, 2022 at 9:45 am

    Edward T. Ryan, M.D., Mary E. Wilson, M.D., and Kevin C. Kain, M.D. Table 1. Table 1. Common or Important Infectious Diseases That May Cause Fever in Travelers ...

  • Drug discovery and development for neglected parasitic diseases
    on February 23, 2022 at 5:06 pm

    Other related organizations such as the Institute for OneWorld Health (iOWH), WHO/TDR, Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases Initiative (DNDi) have functioned ...

  • 2009 in Review: Synopsis of Noteworthy FDA Approvals
    on February 13, 2022 at 5:59 am

    Botulinum toxins: The generic names associated with products containing botulinum toxins A and B were changed to emphasize that the products are not interchangeable. Heightened emphasis of the ...

  • Chronic myeloid leukaemia
    on November 12, 2021 at 5:16 am

    Drugs: Targeted therapy with Imatinib, Nilotinib or Dasatinib is initiated as soon as the cancer has been diagnosed. These medicines slow the progression of cancer. The tablets need to be taken ...

  • Emerging principles in protease-based drug discovery
    on September 1, 2020 at 9:22 am

    Indeed, the hugely successful kinase inhibitor imatinib (Gleevec ... for this is provided by the aminopeptidases (APNs). The malaria parasite Plasmodium falciparum produces eight different ...

via Bing News

The Latest on: Imatinib and malaria

via Google News

Add Comment

Click here to post a comment

Your thoughtful comments are most welcome!

This site uses Akismet to reduce spam. Learn how your comment data is processed.